Home » Stocks » TFFP

TFF Pharmaceuticals, Inc. (TFFP)

Stock Price: $11.98 USD 0.31 (2.66%)
Updated Apr 23, 2021 10:47 AM EDT - Market open
Market Cap 282.81M
Revenue (ttm) n/a
Net Income (ttm) -18.57M
Shares Out 20.43M
EPS (ttm) -2.60
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day April 23
Last Price $11.98
Previous Close $11.67
Change ($) 0.31
Change (%) 2.66%
Day's Open 11.61
Day's Range 11.49 - 12.05
Day's Volume 45,643
52-Week Range 4.31 - 21.14

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation

AUSTIN, Texas--(BUSINESS WIRE)---- $TFFP #DARPA--TFF Pharmaceuticals awarded contract under DARPA's Next-Generation Personalized Protective Biosystems Program for U.S. warfighters.

1 week ago - Business Wire

AUSTIN, Texas--(BUSINESS WIRE)---- $TFFP--TFF Pharmaceuticals prices offering of common stock

4 weeks ago - Business Wire

AUSTIN, Texas--(BUSINESS WIRE)---- $TFFP #earnings--TFF Pharmaceuticals (NASDAQ: TFFP), reports Fourth Quarter and Full Year 2020 financial and business results. Conference call today at 4:30pm EST.

1 month ago - Business Wire

RADNOR, Pa. and AUSTIN, Texas, March 9, 2021 /PRNewswire/ -- NeuroRx, Inc. and TFF Pharmaceuticals, Inc. (NASDAQ: TFFP) are announcing that the companies have entered into a feasibility and material tra...

1 month ago - PRNewsWire

MEDFORD, Mass. & AUSTIN, Texas--(BUSINESS WIRE)---- $TFFP #COVID--GreenLight Biosciences and TFF Pharmaceuticals enter into feasibility arrangement for shelf-stable powder form of messenger RNA COVID-19...

1 month ago - Business Wire

TFF Pharmaceuticals (TFFP) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

1 month ago - Zacks Investment Research

AUSTIN, Texas--(BUSINESS WIRE)---- $TFFP--TFF Pharmaceuticals to Present at the upcoming H.C. Wainwright Global Life Sciences Conference and the 33rd Annual ROTH Conference in March.

1 month ago - Business Wire

AUSTIN, Texas--(BUSINESS WIRE)---- $TFFP #tacrolimus--TFF Pharmaceuticals provides update on its clinical development programs for Voriconazole Inhalation Powder and Tacrolimus Inhalation Powder.

1 month ago - Business Wire

AUSTIN, Texas--(BUSINESS WIRE)---- $TFFP #earnings--TFF Pharmaceuticals to hold its fourth quarter and full-year 2020 financial results and business results conference call on March 10, 2021.

1 month ago - Business Wire

AUSTIN, Texas--(BUSINESS WIRE)---- $TFFP #Ebola--TFF Pharmaceuticals reports positive preclinical results with two biodefense countermeasures for the Army's USAMRIID laboratories.

2 months ago - Business Wire

AUSTIN, Texas--(BUSINESS WIRE)--TFF Pharmaceuticals, Inc. (NASDAQ: TFFP), a clinical-stage biopharmaceutical company focused on developing and commercializing innovative drug products based on its paten...

2 months ago - Business Wire

AUSTIN, Texas--(BUSINESS WIRE)--TFF Pharmaceuticals to present at H.C. Wainwright Virtual BioConnect 2021 Conference, with a corporate presentation available on January 11, 6AM ET.

3 months ago - Business Wire

AUSTIN, Texas--(BUSINESS WIRE)--TFF Pharmaceuticals announces first dosing of asthma patients with Voriconazole Inhalation Powder in a Ph.1b clinical trial for the treatment of IPA.

4 months ago - Business Wire

AUSTIN, Texas--(BUSINESS WIRE)-- #Jefferies--TFF Pharmaceuticals to present at the Jefferies Virtual London Healthcare Conference, with a corporate presentation on November 19, at 2:55 PM ET.

5 months ago - Business Wire

TFF Pharmaceuticals, Inc. (TFFP) CEO Glenn Mattes on Q3 2020 Results - Earnings Call Transcript

5 months ago - Seeking Alpha

AUSTIN, Texas--(BUSINESS WIRE)--TFF Pharmaceuticals reports third quarter 2020 financial and business results - Conference call today, Thursday, November 5, 2020 at 4:30pm ET

5 months ago - Business Wire

AUSTIN, Texas--(BUSINESS WIRE)--TFF Pharmaceuticals and Felix Biotechnology sign Letter of Intent for a Collaboration, Development and License Agreement for bacteriophage therapies.

5 months ago - Business Wire

AUSTIN, Texas & MENLO PARK, Calif.--(BUSINESS WIRE)--TFF Pharmaceuticals and Augmenta Bioworks enter into a worldwide joint development agreement for COVID-19 monoclonal antibody therapies.

5 months ago - Business Wire

AUSTIN, Texas--(BUSINESS WIRE)--TFF Pharmaceuticals announces third quarter 2020 financial results and business update conference call on November 5, 2020.

5 months ago - Business Wire

TFF possess the rights to a game-changing drug formulation technology. They have a cost-efficient, fast route to market for their improved drugs.

5 months ago - Seeking Alpha

AUSTIN, Texas--(BUSINESS WIRE)--TFF Pharmaceuticals announces positive preclinical results with University of Georgia universal influenza vaccines.

5 months ago - Business Wire

AUSTIN, Texas--(BUSINESS WIRE)--TFF Pharmaceuticals expands its cGMP manufacturing capabilities with Experic by installing a Thin Film Freezing processing line.

5 months ago - Business Wire

AUSTIN, Texas--(BUSINESS WIRE)--TFF Pharmaceuticals updates progress of human clinical trial with Tacrolimus Inhalation Powder for prevention of lung transplant rejection.

6 months ago - Business Wire

AUSTIN, Texas--(BUSINESS WIRE)--TFF Pharmaceuticals announces results of its 2020 Annual Meeting of Stockholders

6 months ago - Business Wire

AUSTIN, Texas--(BUSINESS WIRE)--TFF Pharmaceuticals comments on animal studies in the development of high potency remdesivir as a dry powder for inhalation by Thin Film Freezing.

6 months ago - Business Wire

AUSTIN, Texas--(BUSINESS WIRE)--TFF Pharmaceuticals (NASDAQ: TFFP) announces topline results of Voriconazole Inhalation Powder Phase 1 clinical trial.

7 months ago - Business Wire

AUSTIN, Texas--(BUSINESS WIRE)--TFF Pharmaceuticals to participate in Anti-fungal Webinar presented by Maxim Group LLC on September 17th, 2020

7 months ago - Business Wire

AUSTIN, Texas--(BUSINESS WIRE)--TFF Pharmaceuticals, Inc. (NASDAQ: TFFP) will present at the H.C.

7 months ago - Business Wire

With Wall Street set to see its best August in 36 years on coronavirus cure optimism, Fed's plan to keep rates low and upbeat consumer confidence put spotlight on stocks with best month-to-date gains.

Other stocks mentioned: BMCH, CRM, LOB, LQDT
7 months ago - Zacks Investment Research

TFF Pharmaceuticals: Undervalued Novel Drug Manufacturing Technique

7 months ago - Seeking Alpha

TFF Pharmaceuticals (NASDAQ: TFFP) shares are trading higher after the company on Thursday reported a global licensing deal with UNION therapeutics for its Thin Film Freezing technology in combination w...

8 months ago - Benzinga

TFF Pharmaceuticals, Inc. (TFFP) CEO Glenn Mattes on Q2 2020 Results - Earnings Call Transcript

8 months ago - Seeking Alpha

HELLERUP, Denmark, Aug. 13, 2020 /PRNewswire/ -- Niclosamide identified as a potent inhibitor of SARS-Cov-2 by Institut Pasteur Korea, with potency >40x higher than remdesivir UNION has advanced niclosa...

8 months ago - PRNewsWire

AUSTIN, Texas--(BUSINESS WIRE)--TFF Pharmaceuticals in worldwide licensing agreement with UNION therapeutics for its Thin Film Freezing technology in combination with niclosamide.

8 months ago - Business Wire

AUSTIN, Texas--(BUSINESS WIRE)--TFF Pharmaceuticals (NASDAQ:TFFP) reports second quarter 2020 financial and business results - Conference call today at 4:30 PM ET

8 months ago - Business Wire

AUSTIN, Texas--(BUSINESS WIRE)--TFF Pharmaceuticals, Inc. (NASDAQ: TFFP), announces $25.9 million in private financing to further advance its Thin Film Freezing technology platform.

8 months ago - Business Wire

AUSTIN, Texas--(BUSINESS WIRE)--TFF Pharmaceuticals, Inc. (NASDAQ: TFFP), it will release its second quarter 2020 financial results on August 13, 2020 at 4:00 PM ET.

8 months ago - Business Wire

AUSTIN, Texas--(BUSINESS WIRE)--TFF Pharmaceuticals, Inc. (NASDAQ: TFFP) announces completion of dosing for Voriconazole Inhalation Powder Phase 1 clinical trial.

8 months ago - Business Wire

AUSTIN, Texas--(BUSINESS WIRE)--TFF Pharmaceuticals Comments on Research on the Re-formulation of Remdesivir to a Dry Powder Form for COVID-19 Antiviral Treatment

8 months ago - Business Wire

TFF Pharmaceuticals' (TFFP) CEO Glenn Mattes on Q1 2020 Results - Earnings Call Transcript

11 months ago - Seeking Alpha

About TFFP

TFF Pharmaceuticals, Inc., an early-stage biopharmaceutical company, focuses on developing and commercializing drug products based on its patented Thin Film Freezing, or TFF, technology platform in the United States and Australia. It intends to initially focus on the development of inhaled dry powder drugs for the treatment of pulmonary diseases and conditions. The company's lead drug candidates are TFF Voriconazole Inhalation Powder, which has completed Phase I clinical trials for the treatment of invasive pulmonary aspergillosis; and TFF Tacr... [Read more...]

Industry
Biotechnology
IPO Date
Oct 25, 2019
Stock Exchange
NASDAQ
Ticker Symbol
TFFP
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecasts

According to 3 analysts, the average rating for TFFP stock is "Buy." The 12-month stock price forecast is 31.00, which is an increase of 158.76% from the latest price.

Price Target
$31.00
(158.76% upside)
Analyst Consensus: Buy